NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on May 10, 2024, for a proposed sale of securities. The registration includes up to 3,050,964 ordinary shares and ordinary warrants to purchase up to 2,980,000 ordinary shares. The ordinary warrants were acquired under a securities purchase agreement dated April 10, 2024, and 70,964 ordinary shares were issued to the placement agent as partial consideration for their services in connection with the offering. The commencement of the proposed sale to the public is to occur as soon as practicable after the effective date of the registration statement. The selling shareholders will receive all proceeds from the sale of shares and warrants, with NeuroSense incurring...Show More

NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on May 10, 2024, for a proposed sale of securities. The registration includes up to 3,050,964 ordinary shares and ordinary warrants to purchase up to 2,980,000 ordinary shares. The ordinary warrants were acquired under a securities purchase agreement dated April 10, 2024, and 70,964 ordinary shares were issued to the placement agent as partial consideration for their services in connection with the offering. The commencement of the proposed sale to the public is to occur as soon as practicable after the effective date of the registration statement. The selling shareholders will receive all proceeds from the sale of shares and warrants, with NeuroSense incurring offering-related expenses. The company may also receive proceeds from the exercise of the ordinary warrants, provided they are exercised for cash. The ordinary shares and warrants to purchase ordinary shares are listed on The Nasdaq Capital Market under the symbols 'NRSN' and 'NRSNW' respectively. The closing prices for the ordinary shares and warrants on May 9, 2024, were $1.1738 and $0.18, respectively. Investing in NeuroSense's securities involves risks, including the speculative nature of the investment and potential loss of the investment.